GFGeoffrey C. Farrell

Geoffrey C. Farrell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Geoffrey C. Farrell has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Isabelle Leclercq

    Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, Australia

    4 shared publications
  • Graham Robertson

    Faculty of Pharmacy, University of Sydney, NSW, Australia

    3 shared publications
  • Narci Teoh

    Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, Australia

    3 shared publications
  • Aileen Dela Pena

    Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, Australia

    2 shared publications
  • Emilia Ip

    Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, Australia

    2 shared publications
  • Geoffrey William McCaughan

    Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia

    2 shared publications

Latest Publications

  • Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C

    by Priyanka Bandara, Jacob George, Geoffrey McCaughan, Daya Naidoo, Ora Lux, Chris Salonikas, James Kench, Karen Byth, Geoffrey C Farrell

    Background: This study addressed the suggested association between levels of the antioxidants glutathione (GSH), vitamin C and vitamin E in peripheral blood and the histological activity and fibrosis stage in chronic hepatitis C (CHC). We then determined whether regular antioxidant supplementation influenced these antioxidant levels or disease severity.Methods: Clinical, biochemical, histological and demographic data were collected from 247 CHC patients at the time of liver biopsy. Whole blood total GSH, plasma vitamin C and E were assessed by high‐performance liquid chromatography. Statistical analyses were performed to test for associations between the variables and to identify independent predictors for hepatic necroinflammatory and fibrosis scores.Results: GSH and vitamin C, but not vitamin E correlated with both portal/periportal activity (r=−0.19, P=0.004; r=−0.19, P=0.009 respectively) and fibrosis stage (r=−0.18, P=0.007; r=−0.18, P=0.009 respectively). GSH was an independent negative predictor of portal/periportal inflammation (P=0.02) and fibrosis (P=0.01). Vitamin C was an independent negative predictor of fibrosis stage (P=0.02). Antioxidant intake was associated with higher vitamin C (PP=0.005) levels, but not GSH.Conclusions: Whole blood GSH and plasma vitamin C are negatively associated with hepatic portal/periportal inflammation and fibrosis stage in CHC. Controlled intervention studies with vitamin C and agents that boost endogenous GSH levels are warranted.


  • Open Access

    Probing Prometheus: Fat Fueling the Fire?

    by Geoffrey C. Farrell


  • Management of chronic hepatitis C virus infection: a new era of disease control

    by N. C. Teoh, G. C. Farrell

    The management of chronic viral hepatitis has changed significantly with the availability of effective antiviral agents. There is now a high probability that timely intervention can arrest development of cirrhosis, thereby preventing mortality from portal hypertension, liver failure and liver cancer. This two‐part review discusses the implications of this new era of antiviral therapy for physicians. The present review is about chronic hepatitis C virus (HCV); a similar review that considers the treatment of hepatitis B virus will be published in a later issue of theInternal Medicine Journal. Chronic HCV infection is common, but fibrotic progression of liver disease is slow and variable; many infected persons never develop cirrhosis. Case selection for antiviral therapy is crucial. The most effective therapy is a pegylated (long‐acting) interferon with ribavirin. Sustained viral response (SVR) (absent viraemia 6 months after completing treatment) can be obtained in 40−60% of individuals infected with genotype 1 and in approximately 67% with genotype 4 after 12 months of treatment. Response rates are higher (75−85%) with genotypes 2 and 3 after only 6 months of treatment. Late relapse is negligible after SVR. This viral cure reverses hepatic fibrosis, reduces the risk of liver failure and of hepato­cellular carcinoma. Combination therapy requires a supportive setting to minimize the impact of side‐effects and maximize therapeutic effectiveness. Overall management of HCV‐infected persons must also embrace measures to improve quality of life by preventing or dealing with psychosocial issues and advocating lifestyle changes to counter comorbidity from alcohol, central obesity and insulin resistance. These latter factors favour fibrotic disease progression, complications of cirrhosis (such as hepatocellular carcinoma) and development of type 2 diabetes mellitus, as well as eroding the chances of SVR with antiviral therapy. (Intern Med J 2004; 34: 324−337)


  • Open Access

    Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice

    by Emilia Ip, Geoff Farrell, Pauline Hall, Graham Robertson, Isabelle Leclercq

    Administration of a methionine and choline deficient (MCD) diet to rodents causes progressive fibrosing steatohepatitis pathologically similar to human metabolic steatohepatitis. We have previously shown that the peroxisome proliferator-activated receptor-α (PPARα) agonist, Wy-14,643, prevented the development of MCD diet-induced steatohepatitis. We have now tested whether Wy-14,643 ameliorates established steatohepatitis and fibrosis. Male C57BL6 mice were fed the MCD diet for 51 days to induce severe steatohepatitis. They were then treated with Wy-14,643 together with the MCD diet for 5 or 12 days; positive controls continued on the MCD diet for 5 or 12 days. After 5 days of Wy-14,643 treatment, alanine aminotransferase (ALT) levels were significantly decreased, steatohepatitis less severe, and hepatic lipoperoxides significantly reduced. After 12 days, hepatic triglycerides were normalized and there was near resolution of histological changes. MCD dietary feeding was associated with increased expression of vascular cell adhesion molecule (VCAM)-1, and increased numbers of activated macrophages in the liver. Treatment with Wy-14,643 reduced VCAM-1 expression and macrophage numbers. MCD diet-fed mice developed hepatic fibrosis with increased hepatic collagen α1(I), tissue inhibitor of metalloproteinases (TIMP)-1, TIMP-2, and matrix metalloproteinase (MMP)-13 mRNA levels. After treatment with Wy-14,643, expression of these genes was reduced in a manner that paralleled the reduction in activated hepatic stellate cells and near resolution of liver fibrosis. In conclusion, the present study shows that MCD diet-induced fibrosing steatohepatitis can be reversed by treatment with Wy-14,643. It is likely that activation of PPARα reverses fibrosis indirectly by reducing stimuli, such as lipid peroxides, and activation of cells responsible for promoting hepatic fibrosis. (Hepatology 2004;39:1286-1296.)


  • Open Access

    Dual role of tumor necrosis factor-α in hepatic ischemia-reperfusion injury: Studies in tumor necrosis factor-α gene knockout mice

    by Narci Teoh, Jacqueline Field, Jaim Sutton, Geoffrey Farrell

    Although hepatic ischemia-reperfusion (IR) injury is partially mediated by tumor necrosis factor-α (TNF), we recently found that low-dose TNF before IR is hepatoprotective. We examined the seemingly conflicting roles of TNF in mediating liver injury in a partial hepatic IR model using TNF gene knockout (TNF ko) mice to allow TNF replacement at specified times. Compared with wild-type mice, TNF ko mice exhibit minimal alanine aminotransferase release and few hepatonecrotic lesions during the early (time, 2 hours) and late (time, 24 hours) phases of IR. TNF ko mice differed from wild-type mice in that TNF ko mice exhibited no activation or induction of nuclear factor-κ B, p38, cyclin D1, or proliferating cell nuclear antigen after IR. A single low-dose TNF injection 1 minute before the onset of hepatic ischemia restored hepatic IR injury in TNF ko mice. To clarify the importance of TNF for hepatoprotection, preconditioning (10 minutes of ischemia and 10 minutes of reperfusion) was performed before the onset of IR for TNF ko mice whose capacity to undergo IR injury had been restored by TNF replacement. Ischemic preconditioning failed to protect these mice from TNF-augmented IR injury; however, following the administration of intravenous TNF (1 μg per kg body weight, which mimics the early increase in hepatic and plasma TNF levels that is mobilized by ischemic preconditioning), significant hepatoprotection against both the early and late phases of TNF-augmented IR injury was observed. In conclusion, TNF appears to mediate both the early and late phases of liver injury in hepatic IR, but it also is an essential mediator of hepatoprotective effects brought about by ischemic preconditioning. (Hepatology 2004;39:412-421.)


  • Top Cited Papers
    Open Access

    Hepatic ischemia reperfusion injury: Pathogenic mechanisms and basis for hepatoprotection

    by Narci C Teoh, Geoffrey C Farrell

    Abstract  This review highlights recent advances in our understanding of mechanisms underlying reperfusion injury to the liver after warm hepatic ischemia. Sinusoidal endothelial cells and hepatocytes are targets of injury in the early ‘cytotoxic’ phase, although participation of apoptosis in the cell‐death process remains contentious. Kupffer cells may play an important role as the initial cytotoxic cell type and are likely a source of reactive oxygen species and proinflammatory mediators, particularly tumor necrosis factor (TNF)‐α. The latter are involved with subsequent neutrophil activation and recruitment. Microcirculatory disruption results from an imbalance between the actions of vasoconstrictors and vasodilators, such as nitric oxide, and also has a major impact on reperfusion injury. There is growing evidence that a brief prior ischemia–reperfusion period, termed ‘ischemic preconditioning’, is hepatoprotective. This can be mimicked by drugs that produce oxidative stress, and by interleukin‐6 and TNF‐α; both these cytokines are involved with priming hepatocytes to enter the cell cycle. Several mechanisms have been implicated including mobilization of adenosine and activation of adenosine type 2 receptors, nitric oxide, abrogation of TNF synthesis, preservation of energy metabolism, protection of the microcirculation and accelerated cell‐cycle entry. A better understanding of preconditioning mechanisms will lead to novel approaches to improve outcomes of liver surgery.


  • Top Cited Papers
    Open Access

    Central Role of Pparα–Dependent Hepatic Lipid Turnover in Dietary Steatohepatitis in Mice

    by Emilia Ip, Geoffrey C. Farrell, Graham Robertson, Pauline Hall, Richard Kirsch, Isabelle Leclercq

    We have proposed that steatohepatitis results from reactive oxygen species (ROS) acting on accumulated fatty acids to form proinflammatory lipoperoxides. Cytochrome P450 4a (Cyp4a) and Cyp2e1 are potential hepatic sources of ROS. We tested the hypothesis that increasing Cyp4a through activation of peroxisome proliferator–activated receptor α (PPARα) should aggravate steatohepatitis produced by feeding a methionine and choline deficient (MCD) diet. Conversely, we assessed dietary steatohepatitis in PPARα-/- mice that cannot up–regulate Cyp4a. Male wild type (wt) or PPARα-/- mice (C57BL6 background) were fed the MCD diet with or without Wy–14,643 (0.1% wt/wt), a potent PPARα agonist. Controls were fed the same diet supplemented with methionine and choline. After 5 weeks, wt mice fed the MCD diet developed moderate steatohepatitis and alanine aminotransferase (ALT) levels were increased. Wy–14,643 prevented rather than increased liver injury; ALT levels were only mildly elevated whereas steatohepatitis was absent. Wy–14,643 up–regulated mRNA for liver fatty acid binding protein and peroxisomal β–oxidation enzymes (acyl–CoA oxidase, bifunctional enzyme, and ketothiolase), thereby reducing hepatic triglycerides and preventing steatosis. In wt mice, dietary feeding up–regulated Cyp4a14 mRNA 2.7–fold and increased hepatic lipoperoxides compared with controls. Wy–14,643 prevented hepatic lipoperoxides from accumulating despite an 18–fold increase in both Cyp4a10 and Cyp4a14 mRNA. PPARα-/- mice fed the MCD diet developed more severe steatohepatitis than wt mice, and were unaffected by Wy–14,643. In conclusion, PPARα activation both increases Cyp4a expression and enhances hepatic lipid turnover; the latter effect removes fatty acids as substrate for lipid peroxidation and is sufficiently powerful to prevent the development of dietary steatohepatitis.


  • How reversible is hepatic functional impairment in autoimmune hepatitis?

    by Shirley A Coverdale, Jacqueline Field, Geoffrey C Farrell

    Background and Aims: We quantifed the short‐term effects of immunosuppressive therapy on hepatic metabolic function in autoimmune hepatitis to establish how long it takes to achieve maximum functional improvement.Methods: We studied 14 newly diagnosed patients with autoimmune hepatitis (12 type 1, two type 2) by antipyrine clearance and conventional liver tests, then repeated studies at 3–6 month intervals during the first 18 months of immunosuppressive therapy.Results: Low values for antipyrine clearance were found in 13 of 14 cases; serum albumin concentration was low in four, bilirubin raised in eight and prothrombin time prolonged in four. Following immunosuppressive treatment for 3 months, antipyrine clearance improved by 98% (standard error of the mean 24%), which was proportionally greater than for serum albumin, bilirubin or prothrombin time. Antipyrine clearance and serum albumin continued to improve after 6–12 months of immunosuppressive treatment in several cases, whereas there were no further improvements in alanine aminotransferase (ALT), bilirubin and prothrombin time.Conclusions: In the short term, immunosuppressive therapy for autoimmune hepatitis markedly improves hepatic metabolic function, which is particularly striking for the sensitive metabolic test antipyrine clearance, but may also be seen with serum albumin. However, it may take up to 12 months to achieve maximal functional recovery. Management guidelines on autoimmune hepatitis should be extended to emphasize that changes in hepatic metabolic function, as well as ALT and γ‐globulin levels, be taken into consideration in the definition of remission.© 2003 Blackwell Publishing Asia Pty Ltd